Hamberger & Weiss LLP


CMS Lowers Meloxicam Pricing, Will Result in Some Lower WCMSAs

In April 2020, CMS began using significantly lower pricing for meloxicam, reducing the pricing from over four dollars a pill to five cents a pill in the 7.5 mg and 15 mg formulations. Historically, meloxicam has been one of the highest priced non-steroidal anti-inflammatory drugs commonly prescribed in workers' compensation claims. The lower CMS pricing for meloxicam will result in lower WCMSAs, permitting the settlement of cases previously thought too expensive to settle due to the cost of this medication.

We recommend that our clients review their files for cases previously deemed too expensive to settle to determine whether meloxicam was the primary cost driver. Please do not hesitate to contact our partner Dan Bowers with any questions.

Back to News

Copyright © 2023 Hamberger & Weiss LLP